Erythrocyte glutathione and tumour response to chemotherapy.
There is much evidence that tumour glutathione (GSH) concentration is an important factor in resistance to cancer chemotherapy. Since measurement of tumour GSH would require an invasive procedure in every patient, we have tried to find out whether GSH concentrations in peripheral-blood erythrocytes are related to the response to chemotherapy and thus whether they reflect those in tumour cells. Erythrocyte GSH concentrations were measured by spectrophotometry in peripheral blood from 28 patients with advanced breast cancer and 40 patients with other tumours before and after treatment with various conventional chemotherapeutic regimens. The mean pretreatment GSH concentration was lower in patients who showed a complete or partial response to chemotherapy than in those with stable or progressive disease in both the breast-cancer group (8.69 [95% confidence interval 5.99-11.39] vs 2.32 [1.23-3.41] mumol/g haemoglobin; p less than 0.01) and the group with other tumours (5.94 [4.14-7.74] vs 2.83 [1.71-3.95] mumol/g; p less than 0.01). The correlation of erythrocyte GSH concentration with response rate suggests that this measurement may be helpful in prediction of response to therapy.
Hercbergs
A
A
Department of Radiation Therapy, Cleveland Clinic Foundation, Ohio 44195-5213.
Brok-Simoni
F
F
Holtzman
F
F
Bar-Am
J
J
Leith
J T
JT
Brenner
H J
HJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004912:Erythrocytes / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005978:Glutathione / Q000097:blood*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D011237:Predictive Value of Tests
D000970:Antineoplastic Agents; D005978:Glutathione